Notify me when Avoro Capital Advisors LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 33 | $10,121,718,832 | +$1,789,220,530 | -$1,115,245,802 | +$673,974,728 | UTHR, ASND, MDGL, ARGX, KRYS | 13F-HR | 17 Feb 2026, 07:21 |
| Q3 2025 | 30 | $7,729,823,545 | +$575,094,026 | -$488,687,315 | +$86,406,711 | ASND, UTHR, MDGL, ARGX, KRYS | 13F-HR | 14 Nov 2025, 07:10 |
| Q2 2025 | 30 | $5,710,277,507 | +$333,847,805 | -$1,135,122,878 | -$801,275,073 | ASND, UTHR, ARGX, MDGL, KRYS | 13F-HR | 14 Aug 2025, 08:00 |
| Q1 2025 | 33 | $6,406,567,714 | +$441,319,280 | -$619,061,424 | -$177,742,144 | UTHR, ASND, ARGX, MDGL, KRYS | 13F-HR | 15 May 2025, 06:55 |
| Q4 2024 | 39 | $7,069,981,381 | +$537,904,563 | -$168,298,472 | +$369,606,091 | UTHR, ARGX, ASND, MDGL, KRYS | 13F-HR | 14 Feb 2025, 08:34 |
| Q3 2024 | 35 | $6,858,026,355 | +$301,228,516 | -$1,128,358,712 | -$827,130,196 | UTHR, ASND, ARGX, KRYS, MDGL | 13F-HR | 14 Nov 2024, 07:59 |
| Q2 2024 | 41 | $7,508,400,483 | +$255,296,045 | -$1,179,503,359 | -$924,207,314 | UTHR, MDGL, ASND, ARGX, SRPT | 13F-HR | 14 Aug 2024, 07:58 |
| Q1 2024 | 46 | $8,573,512,829 | +$1,703,672,329 | -$873,497,371 | +$830,174,958 | UTHR, APLS, ASND, SRPT, MDGL | 13F-HR | 15 May 2024, 08:07 |
| Q4 2023 | 42 | $7,239,756,496 | +$1,496,505,071 | -$1,480,185,579 | +$16,319,492 | APLS, UTHR, ASND, ARGX, MDGL | 13F-HR | 14 Feb 2024, 12:05 |
| Q3 2023 | 45 | $6,409,999,031 | +$265,707,460 | -$764,094,775 | -$498,387,315 | HZNP, UTHR, ARGX, SRPT, APLS | 13F-HR | 14 Nov 2023, 06:32 |
| Q2 2023 | 43 | $7,371,201,102 | +$486,142,261 | -$166,011,824 | +$320,130,437 | APLS, HZNP, UTHR, SRPT, ARGX | 13F-HR | 14 Aug 2023, 07:33 |
| Q1 2023 | 38 | $6,739,485,093 | +$304,214,023 | -$21,427,488 | +$282,786,535 | HZNP, APLS, UTHR, SRPT, ARGX | 13F-HR | 15 May 2023, 09:09 |
| Q4 2022 | 36 | $6,691,518,386 | +$472,698,953 | -$55,749,735 | +$416,949,218 | UTHR, HZNP, APLS, MDGL, ARGX | 13F-HR | 14 Feb 2023, 09:04 |
| Q3 2022 | 39 | $5,412,850,000 | +$264,383,922 | -$195,536,506 | +$68,847,416 | APLS, UTHR, ARGX, MRTX, SRPT | 13F-HR | 14 Nov 2022, 09:28 |
| Q2 2022 | 40 | $5,060,568,000 | +$321,859,556 | -$394,859,197 | -$72,999,641 | UTHR, ARGX, APLS, HZNP, MRTX | 13F-HR | 15 Aug 2022, 08:54 |
| Q1 2022 | 43 | $5,477,565,000 | +$788,768,564 | -$411,273,703 | +$377,494,861 | HZNP, UTHR, APLS, MRTX, ARGX | 13F-HR | 16 May 2022, 08:57 |
| Q4 2021 | 40 | $5,862,620,000 | +$640,422,254 | -$1,229,129,998 | -$588,707,744 | HZNP, MRTX, UTHR, APLS, ARGX | 13F-HR | 14 Feb 2022, 09:03 |
| Q3 2021 | 43 | $6,338,733,000 | +$602,993,544 | -$363,618,520 | +$239,375,024 | HZNP, MRTX, XLRN, UTHR, ASND | 13F-HR | 15 Nov 2021, 09:04 |
| Q2 2021 | 44 | $5,743,703,000 | +$644,089,572 | -$497,541,121 | +$146,548,451 | HZNP, MRTX, UTHR, XLRN, ARGX | 13F-HR | 16 Aug 2021, 09:05 |
| Q1 2021 | 46 | $5,790,264,000 | +$1,094,159,675 | -$373,203,423 | +$720,956,252 | HZNP, MRTX, UTHR, XLRN, VRTX | 13F-HR | 17 May 2021, 09:29 |
| Q4 2020 | 43 | $5,806,497,000 | +$1,137,373,807 | -$3,071,981,534 | -$1,934,607,727 | MRTX, HZNP, UTHR, IOVA, ARNA | 13F-HR | 16 Feb 2021, 12:33 |
| Q3 2020 | 46 | $7,038,431,000 | +$727,334,026 | -$353,003,695 | +$374,330,331 | IMMU, MRTX, HZNP, IOVA, ASND | 13F-HR | 16 Nov 2020, 09:02 |
| Q2 2020 | 44 | $5,057,950,000 | +$742,808,471 | -$192,987,946 | +$549,820,525 | IMMU, MRTX, HZNP, IOVA, SRPT | 13F-HR | 14 Aug 2020, 10:00 |
| Q1 2020 | 41 | $2,959,530,000 | +$489,259,712 | -$50,671,102 | +$438,588,610 | IMMU, MRTX, IOVA, ASND, BMRN | 13F-HR | 15 May 2020, 13:03 |
| Q4 2019 | 29 | $3,400,498,000 | +$494,413,171 | -$515,019,338 | -$20,606,167 | IMMU, MRTX, ASND, IOVA, SRPT | 13F-HR | 14 Feb 2020, 09:47 |
| Q3 2019 | 33 | $2,397,262,000 | +$220,357,410 | -$168,499,583 | +$51,857,827 | MRTX, IMMU, IOVA, ASND, BMRN | 13F-HR | 14 Nov 2019, 12:40 |
| Q2 2019 | 33 | $2,887,228,000 | +$530,699,997 | -$176,293,159 | +$354,406,838 | MRTX, IMMU, IOVA, ASND, SRPT | 13F-HR | 14 Aug 2019, 12:04 |
| Q1 2019 | 31 | $2,311,337,000 | +$299,236,163 | -$249,063,012 | +$50,173,151 | IMMU, MRTX, ASND, AMRN, SRPT | 13F-HR | 15 May 2019, 12:26 |
| Q4 2018 | 33 | $1,671,366,000 | +$198,469,700 | -$305,683,944 | -$107,214,244 | IMMU, MRTX, SRPT, ASND, BMRN | 13F-HR | 14 Feb 2019, 11:11 |
| Q3 2018 | 43 | $2,176,297,000 | +$169,638,967 | -$535,602,808 | -$365,963,841 | IMMU, MRTX, SRPT, ASND, BMRN | 13F-HR | 14 Nov 2018, 11:16 |
| Q2 2018 | 41 | $2,592,366,000 | +$690,163,941 | -$444,283,353 | +$245,880,588 | IMMU, MRTX, BMRN, FOLD, ASND | 13F-HR | 14 Aug 2018, 11:25 |
| Q1 2018 | 50 | $2,087,245,000 | +$560,805,749 | -$147,510,448 | +$413,295,301 | IMMU, FOLD, BMRN, IOVA, MRTX | 13F-HR | 15 May 2018, 12:51 |
| Q4 2017 | 44 | $1,529,439,000 | +$360,297,418 | -$170,540,233 | +$189,757,185 | IMMU, BMRN, FOLD, MRTX, CLVSQ | 13F-HR | 14 Feb 2018, 11:43 |
| Q3 2017 | 39 | $1,272,599,000 | +$445,718,660 | -$152,446,084 | +$293,272,576 | IMMU, FOLD, KITE, ARRY, CLVSQ | 13F-HR | 14 Nov 2017, 12:23 |
| Q2 2017 | 42 | $789,345,000 | +$187,830,519 | -$197,353,846 | -$9,523,327 | IMMU, KITE, FOLD, TSRO, BMRN | 13F-HR | 14 Aug 2017, 12:30 |
| Q1 2017 | 42 | $781,964,000 | +$309,590,023 | -$126,853,550 | +$182,736,473 | IMMU, TSRO, MDCO, ACAD, BMRN | 13F-HR | 15 May 2017, 12:20 |
| Q4 2016 | 39 | $493,936,000 | +$100,590,187 | -$80,964,868 | +$19,625,319 | ACAD, IMMU, BMRN, LBIO, TSRO | 13F-HR | 14 Feb 2017, 12:27 |
| Q3 2016 | 44 | $563,022,000 | +$109,158,848 | -$116,223,833 | -$7,064,985 | SRPT, BMRN, LBIO, TSRO, FOLD | 13F-HR | 14 Nov 2016, 15:38 |
| Q2 2016 | 38 | $445,320,000 | +$184,265,577 | -$41,157,788 | +$143,107,789 | TSRO, LBIO, CPXX, BMRN, BMY | 13F-HR | 15 Aug 2016, 16:09 |
| Q1 2016 | 33 | $283,865,000 | +$128,696,522 | -$52,168,163 | +$76,528,359 | MRTX, FOLD, BMRN, SRPT, GILD | 13F-HR | 16 May 2016, 16:06 |
| Q4 2015 | 28 | $289,672,000 | +$23,368,669 | -$92,168,720 | -$68,800,051 | MRTX, FOLD, LBIO, LJPC, SRPT | 13F-HR | 12 Feb 2016, 12:00 |
| Q3 2015 | 29 | $378,166,000 | +$123,682,574 | -$43,860,024 | +$79,822,550 | FOLD, MRTX, VNDA, NEURODERM LTD., LJPC | 13F-HR | 13 Nov 2015, 12:27 |
| Q2 2015 | 30 | $362,346,000 | +$141,647,649 | -$77,458,869 | +$64,188,780 | FOLD, SRNE, MRTX, LBIO, ONTY | 13F-HR | 14 Aug 2015, 12:31 |
| Q1 2015 | 33 | $260,578,000 | +$137,584,938 | -$39,423,841 | +$98,161,097 | FOLD, LBIO, SRNE, CELGENE CORP., PTX | 13F-HR | 15 May 2015, 11:59 |
| Q4 2014 | 27 | $143,593,000 | $0 | $0 | $0 | FOLD, TARO, RCPT, PTX, AGEN | 13F-HR | 13 Feb 2015, 13:07 |